ketanserin has been researched along with Cardiac Failure in 8 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketanserin is a selective serotonin2-receptor blocker and by this mechanism decreases peripheral resistance and blood pressure in hypertensives." | 5.28 | Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure. ( Brune, S; Kreuzer, H; Schmidt, T; Tebbe, U, 1990) |
| "Ketanserin did not produce any change in catecholamine concentration." | 5.27 | Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure. ( Majid, PA; Morris, WM; Sole, MJ, 1987) |
| " Ketanserin is a highly selective S2-serotonergic antagonist with additional alpha-adrenergic blocking activity, which has been proposed as a therapy for various cardiovascular diseases including hypertension." | 4.79 | Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. ( Frishman, WH; Huberfeld, S; Kumar, A; Okin, S; Shareef, B; Wang, YH, 1995) |
| "Rats with congestive heart failure (CHF) develop ventricular inotropic responsiveness to serotonin (5-HT), mediated through 5-HT(2A) and 5-HT(4) receptors." | 1.34 | Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes. ( Birkeland, JA; Enger, U; Levy, FO; Lunde, PK; Qvigstad, E; Sejersted, OM; Sjaastad, I; Swift, F; Tovsrud, N, 2007) |
| "Ketanserin is a selective serotonin2-receptor blocker and by this mechanism decreases peripheral resistance and blood pressure in hypertensives." | 1.28 | Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure. ( Brune, S; Kreuzer, H; Schmidt, T; Tebbe, U, 1990) |
| "Ketanserin did not produce any change in catecholamine concentration." | 1.27 | Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure. ( Majid, PA; Morris, WM; Sole, MJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birkeland, JA | 1 |
| Swift, F | 1 |
| Tovsrud, N | 1 |
| Enger, U | 1 |
| Lunde, PK | 1 |
| Qvigstad, E | 1 |
| Levy, FO | 1 |
| Sejersted, OM | 1 |
| Sjaastad, I | 1 |
| Demoulin, JC | 1 |
| Bertholet, M | 1 |
| Soumagne, D | 1 |
| David, JL | 1 |
| Kulbertus, HE | 1 |
| Opie, LH | 1 |
| Frishman, WH | 1 |
| Huberfeld, S | 1 |
| Okin, S | 1 |
| Wang, YH | 1 |
| Kumar, A | 1 |
| Shareef, B | 1 |
| Brune, S | 1 |
| Schmidt, T | 1 |
| Tebbe, U | 1 |
| Kreuzer, H | 1 |
| Grobecker, H | 1 |
| Gessler, I | 1 |
| Delius, W | 1 |
| Dominiak, P | 1 |
| Kees, F | 1 |
| Majid, PA | 2 |
| Morris, WM | 1 |
| Sole, MJ | 2 |
1 review available for ketanserin and Cardiac Failure
| Article | Year |
|---|---|
Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Coronary Disease; | 1995 |
7 other studies available for ketanserin and Cardiac Failure
| Article | Year |
|---|---|
Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Calcium Channels, L-Type; Calcium Signaling; C | 2007 |
5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Heart Failure; Hemodynamics; Humans; Ketanserin; Male; | 1981 |
Principles of therapy for congestive heart failure.
Topics: Calcium; Calcium Channel Blockers; Calmodulin; Cardiotonic Agents; Clonidine; Cyclic AMP; Cytosol; D | 1983 |
Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure.
Topics: Aged; Blood Pressure; Cardiac Output; Coronary Disease; Heart Failure; Heart Rate; Humans; Ketanseri | 1990 |
Effect of ketanserin on hemodynamics, plasma-catecholamine concentrations, and serotonin uptake by platelets in volunteers and patients with congestive heart failure.
Topics: Aged; Blood Platelets; Catecholamines; Dopamine; Female; Heart Failure; Hemodynamics; Humans; Ketans | 1985 |
Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Catecholamines; Dopamine; Epinephrine; Heart Failure; Hemodynamic | 1987 |
Effect of 5-hydroxytryptamine blockade with ketanserin on myocardial uptake of epinephrine and norepinephrine in patients with congestive heart failure.
Topics: Adult; Aged; Dopamine; Epinephrine; Heart Failure; Humans; Ketanserin; Male; Middle Aged; Myocardium | 1987 |